

Date: 11/11/2020

To
The Manager
Listing & Compliance
Bombay Stock Exchange (BSE Limited)
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Subject: Outcome of Board Meeting and submission of Un-Audited Financial Results for the Quarter and Half Year Ended 30.09.2020

Ref: Earum Pharmaceuticals Limited
Scrip Code: 542724

Respected Sir/Madam,


With reference to the captioned subject and pursuant to the Regulation 33 of SEBI (LODR) Regulation, 2015, the Board of Directors of the Company at its meeting held on today i.e. Wednesday, 11th November, 2020, inter alia, Considered and approved the unaudited Financial Result, at their respective meeting held today i.e. November 11, 2020 along with Limited Review Report for the quarter and half year ended on 30th September, 2020.

Further please find enclosed herewith the unaudited quarterly and half yearly financial result as on 30.09.2020 along with the limited review report taken on record by the Board of Directors.

Kindly take the same on record.

Thanking you,

For and on behalf of
For Earum Pharmaceuticals Limited


Bhunishth Narendrabhai Patel
(MANAGING DIRECTOR)
DIN: 02516641

EARUM PHARMCEUTICALS LIMITED

CIN: U24230GJ2012PLC071299

Registered Office: "G-1, V R COMPLEX, Nr. SANATHAL CROSS ROAD, S P RING ROAD, SANATHAL, AHMEDABAD-382210"

Phone: +91 79 48402525, E mail: earumpharma@gmail.com, Website: www.earumpharma.com

Part - 1 Standalone Audited Financial Results For The Half Year Ended on 30.09.2020

Sr. No.	Particulars	<i>All amount in Rs. Lacs unless otherwise stated</i>				
		6 months ended			Year Ended	
		30.09.2020 (Unaudited)	31.03.2020 (Audited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)	31.03.2019 (Audited)
1	Revenue from operations					
	(a) Net sales/income from operations (Net of excise duty)	3,885.09	2,715.61	2,795.27	5,510.88	5,070.00
	(b) Other Income	307.63	125.20	102.10	227.30	5.34
	Total Revenue	4,192.72	2,840.81	2,897.37	5,738.18	5,075.34
2	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchase of Stock in Trade	3,542.75	2,492.61	2,789.60	5,282.21	4,885.94
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	525.04	(88.17)	(157.86)	(246.03)	(264.20)
	(d) Employee benefits expense	15.88	15.81	14.38	30.19	38.23
	(e) Finance Cost	45.66	48.72	47.93	96.65	103.94
	(f) Depreciation and amortisation expense	5.97	4.59	5.38	9.97	3.77
	(g) Other expenses	209.36	238.34	82.34	320.68	79.98
	(i) Power Expenses	-	-	-	-	-
	(j) Fuel Expenses	-	-	-	-	-
	Total expenses	4,344.66	2,711.90	2,781.77	5,493.67	4,847.66
	Profit/(Loss) from operations before an Exceptional and Extra ordinary items and Tax (1-2)	(151.94)	128.91	115.60	244.51	227.68
3	Exceptional Items					
4	Profit/(Loss) from ordinary activities before an Extra Ordinary items and Tax (3 - 4)	(151.94)	128.91	115.60	244.51	227.68
5	Extra Ordinary Items					
6	Profit/(Loss) from ordinary activities before tax (5 - 6)	(151.94)	128.91	115.60	244.51	227.68
7	Tax Expense (net)					
	- Current tax	-	32.77	30.21	62.98	61.55
	- Deferred tax	-	-	-	-	-
	Total Tax Expenses	-	32.77	30.21	62.98	61.55
8	Net Profit(Loss) for the Period from continuing operations	(151.94)	96.13	85.39	181.52	166.14
9	Profit(Loss) From Discontinuing operations before tax					
10	Tax Expense of discontinuing Oprations					
11	Net Profit(loss) from discontinuing Oprations after Tax					
12	Profit(loss) for period before minority interest	(151.94)	96.13	85.39	181.52	166.14
13	Share of profits(loss) of subsidiary					
14	Profit(loss) of minority Interest					
15	Net Profit(loss) for the period	(151.94)	96.13	85.39	181.52	166.14
16	Details of Equity share capital					
	(a) Paid up Equity Share capital	616.79	616.79	616.79	616.79	30.85
	(b) face value of Equity share capital(in Rs.)	10.00	10.00	10.00	10.00	10.00

18	Details of Debt Securities					
	(a) Paid up Debt capital	-	-	-	-	
	(b) face value of debt securities	-	-	-	-	
19	Debentures redemption reserve	-	-	-	-	
20	Earnings per share (before extra ordinary items) (of Rs. 10 each) (not annualised):					
	(a) Basic	-2.46	1.56	1.38	2.94	53.83
	(b) Diluted	-2.46	1.56	1.38	2.94	53.83
21	Earnings per share (after extra ordinary items) (of Rs. 10 each) (not annualised):					
	(a) Basic	-2.46	1.56	1.38	2.94	53.83
	(b) Diluted	-2.46	1.56	1.38	2.94	53.83
22	Debt Equity Ratio	1.66	0.35	1.10	1.51	3.33

For, EARUM PHARMACEUTICALS LIMITED

BHUMISHTH PATEL
DIN : 02516641
DATE : 11/11/2020



Part - 2
Statement of Standalone Assets and Liabilities for the half year ended 30.09.2020

Particulars		As At 30.09.2020	As At 31.03.2020
	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	616.79	616.79
	(b) Reserves and surplus	672.56	824.51
	(c) Money Received against share warrants	-	-
	Total Shareholders' funds	1,289.35	1,441.30
2	Share Application money pending allotment	-	-
3	Deferred Government Grants	-	-
4	Minority Interest	-	-
5	Non-current liabilities		
	- Long-term borrowings	27.60	136.93
	- Deferred tax liabilities (net)	1.07	1.07
	- Foreign Currency Monetary Item translation difference liability account	-	-
	- Other long-term liabilities	-	-
	- Long-term provisions	-	-
	Total Non-current liabilities	28.67	138.00
6	Current liabilities		
	- Short-term borrowings	951.01	706.72
	- Trade payables	-	-
	(A) Total outstanding dues of micro enterprises and small enterprises	-	-
	(B) Total outstanding dues of creditors other than micro enterprise and small enterprises	906.64	1,151.24
	- Other current liabilities	193.08	114.87
	- Short-term provisions	63.58	63.58
	Total Current liabilities	2,114.31	2,036.41
	TOTAL EQUITY AND LIABILITIES	3,432.33	3,615.71
	ASSETS		
1	Non-current assets		
	(i) Fixed assets		
	- Tangible assets	80.48	79.64
	- Producing Properties	-	-
	- Intangible Assets	-	-
	- Preproducing Properties	-	-
	- Tangible Assets Capital work-in-progress	-	-
	- Intangible assts under development or work - in - progress	-	-
	Total Fixed Assets	80.48	79.64
	(ii) Non-current investments	254.75	302.70
	(iii) Deferred tax assets (net)	-	-
	(iv) Foreign currency monetary item translation difference asset account	-	-
	(v) Long-term loans and advances	-	-
	(vi) Other non-current assets	-	-
	Total Non-current assets	335.23	382.34

2	Current assets		
	- Current investments	-	-
	- Inventories	814.38	1,339.42
	- Trade receivables	2,038.93	1,695.38
	- Cash and cash equivalents	16.28	2.54
	- Short-term loans and advances	210.40	104.22
	- Other current assets	17.11	91.81
	Total Current assets	3,097.10	3,233.37
	TOTAL - ASSETS	3,432.33	3,615.71

For, EARUM PHARMACEUTICALS LIMITED

BHUMISHTH PATEE

DIN : 02516641

DATE : 11/11/2020



CASHFLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

All amount in Rs. Lacs unless otherwise stated

	For the period Ended 30th September,2020	For the Period Ended 31st March,2020
Cash flows from operating activities		
Profit before taxation	(151.94)	244.51
Adjustments for:		
Depreciation	5.97	9.97
Investment income	-	-
Deferred tax Liability	-	-
Interest expense	45.66	96.65
Profit / (Loss) on the sale of property, plant & equipment	-	-
Working capital changes:		
(Increase) / Decrease in trade and other receivables	(349.53)	(610.86)
(Increase) / (Decrease) in inventories	525.04	(246.03)
(Increase) / (Decrease) in Short Term Loan & Advance	(106.18)	(20.76)
(Increase) / (Decrease) in Other Current Assets	74.70	(91.55)
Increase / (Decrease) in Trade payables	(244.60)	468.85
Increase / (Decrease) in Short term Provisions	-	(10.23)
Increase / (Decrease) in Other Current Liabilities	78.21	(25.55)
Cash generated from operations	(122.67)	(185.00)
Interest paid	(45.66)	(96.65)
Income taxes paid	-	(62.98)
Dividends paid	-	-
Net cash from operating activities	(168.33)	(344.63)
Cash flows from investing activities		
Business acquisitions, net of cash acquired	47.95	(302.70)
Purchase of property, plant and equipment	(0.84)	(42.06)
Proceeds from sale of equipment	-	-
Acquisition of portfolio investments	-	-
Investment income	-	-
Net cash used in investing activities	47.11	(344.76)
Cash flows from financing activities		
Proceeds from issue of share capital	-	184.80
Proceeds from long-term borrowings	(109.33)	(122.11)
Proceeds from Short-term borrowings	244.29	132.67
Payment of Share Application Money	-	-
Share Capital Issue With Security Premium	-	480.47
Net cash used in financing activities	134.96	675.83
Net increase in cash and cash equivalents	13.74	(13.56)
Cash and cash equivalents at beginning of period	2.54	16.10
Cash and cash equivalents at end of period	16.28	2.54

For, EARUM PHARMACEUTICALS LIMITED

BHUMSHETH PATEL

DIN : 02516641

DATE : 11/11/2020



NOTES :

- 1 The above^{On} audited financial results are reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 11th November, 2020.
- 2 Figures have been re-grouped or re-classified, wherever necessary.
- 3 The Company is operating in providing pharmaceuticals Trading.
- 4 Figures of half year ended 31st March, 2020 are the balancing figures between the audited figures of year ended on 31/03/2020 and half year ended on 30/09/2019.
- 5 Provision of Tax has been made as per Income Tax Act, 1961. Tax Expense includes the Current Tax and Provision for Deferred Tax.
- 6 The above financial results are available on companies website www.earumpharma.com and the stock exchange viz. www.bseindia.com

For, EARUM PHARMACEUTICALS LIMITED

BHUMISHTH PATEL

DIN : 02516641

DATE : 11/11/2020



J. M. PATEL & BROS.

CHARTERED ACCOUNTANTS

E-mail : jmpatelca@yahoo.co.in

204, Harsh Avenue,
Navjivan Press Road,
Nr. Old High Court Crossing,
AHMEDABAD - 380 014.
Phone: (079) 27541460

Ref. No. :

Date :

**LIMITED REVIEW REPORT ON FINANCIAL RESULT OF EARUM PHARMACEUTICALS
LIMITED PURSUANT TO REGULATIONS 33 OF THE SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE QUARTER AND HALF
YEAR ENDED 30TH SEPTEMBER, 2020**

To,

The Board of Directors of
Earum Pharmaceuticals Limited


We have reviewed the accompanying statement of unaudited financial results of Earum Pharmaceuticals Limited ("The Company") for Quarter and Half year ended on 30th September, 2020 ("The Statement") attached herewith, being submitted by company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Read with SEBI Circular no. CIR/CFD/FAC/62/2016 Dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognitions and measurement principle laid down in the Indian accounting standard 34 "Internal Financial Reporting" (IND AS-34), prescribed under section 133 of the companies act, 2013 read with relevant rules issued there under and other accounting principle generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent Auditors of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad
Date: 11/11/2020



FOR J M PATEL & BROS.
Chartered Accountants
(FRN: 107707W)

Jashwant M Patel
CA JASHWANT M PATEL
(Proprietor)

(M. No: 030161)
UDIN: 20030161AAAASA5921